RPTX — Repare Therapeutics Share Price
0.000.00%
Last trade - 00:00- $61.33m
- -$91.46m
- $53.48m
- 49
- 60
- 32
- 44
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.41 | ||
| Price to Tang. Book | 0.41 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.15 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -61.85% | ||
| Return on Equity | -46.63% | ||
| Operating Margin | -174.88% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.14 | 7.6 | 131.83 | 51.13 | 53.48 | 9.33 | 10 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes lunresertib (RP-6306), a PKMYT1 inhibitor in Phase 1/2 clinical development; camonsertib (RP-3500), a potential Ataxia-Telangiectasia and Rad3-related protein kinase (ATR) inhibitor in Phase 1/2 clinical development; RP-1664, a Phase 1 PLK4 inhibitor; RP-3467, a preclinical polymerase theta adenosinetriphosphatase (ATPase) inhibitor program, and additional, undisclosed preclinical programs. RP-3500 is a potent and selective oral small molecule inhibitor of ATR in clinical development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations.
Directors
- Thomas Civik CHM (52)
- Lloyd Segal PRE (57)
- Steve Forte CFO (42)
- Michael Zinda EVP (50)
- Maria Koehler EVP (64)
- Jerel Davis DRC (44)
- David Bonita IND (45)
- Todd Foley IND (49)
- Samarth Kulkarni IND (42)
- Briggs Morrison IND (62)
- Ann Rhoads IND (56)
- Carol Schafer IND (57)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- June 23rd, 2020
- Public Since
- June 19th, 2020
- No. of Shareholders
- 10
- No. of Employees
- 129
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 42,891,403
- Address
- 7210 Frederick-Banting, Suite 100, ST-LAURENT, H4S 2A1
- Web
- https://www.reparerx.com/
- Phone
- Auditors
- Ernst & Young LLP
Upcoming Events for RPTX
Repare Therapeutics Inc Annual Shareholders Meeting
Similar to RPTX
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the Repare Therapeutics share price?
As of Today at 22:55 UTC, shares in Repare Therapeutics are trading at $1.43. This share price information is delayed by 15 minutes.
How has the Repare Therapeutics share price performed this year?
Shares in Repare Therapeutics last closed at $1.43 and the price had moved by -57.31% over the past 365 days. In terms of relative price strength the Repare Therapeutics share price has underperformed the S&P500 Index by -61.51% over the past year.
What are the analyst and broker recommendations for Repare Therapeutics?
The overall consensus recommendation for Repare Therapeutics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Repare Therapeutics dividend yield?
Repare Therapeutics does not currently pay a dividend.
Does Repare Therapeutics pay a dividend?
Repare Therapeutics does not currently pay a dividend.
When does Repare Therapeutics next pay dividends?
Repare Therapeutics does not currently pay a dividend.
How do I buy Repare Therapeutics shares?
To buy shares in Repare Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Repare Therapeutics?
As of the previous close price of $1.43, shares in Repare Therapeutics had a market capitalisation of $61.33m.
Where are Repare Therapeutics shares listed?
Here are the trading details for Repare Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: RPTX
What kind of share is Repare Therapeutics?
Based on an overall assessment of its quality, value and momentum Repare Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Repare Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Repare Therapeutics is $6.50. That is 354.55% above the last closing price of $1.43.
Analysts covering Repare Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$2.11 for the next financial year.
Find out moreWhat is the trend in the Repare Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Repare Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -59.87%.
As of the last closing price of $1.43, shares in Repare Therapeutics were trading -38.18% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Repare Therapeutics PE Ratio?
The Repare Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.43.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Repare Therapeutics?
Repare Therapeutics' management team is headed by:
- Thomas Civik - CHM
- Lloyd Segal - PRE
- Steve Forte - CFO
- Michael Zinda - EVP
- Maria Koehler - EVP
- Jerel Davis - DRC
- David Bonita - IND
- Todd Foley - IND
- Samarth Kulkarni - IND
- Briggs Morrison - IND
- Ann Rhoads - IND
- Carol Schafer - IND